Full Text View
Tabular View
No Study Results Posted
Related Studies
Droxidopa in Treating Patients With Neurogenic Hypotension
This study has been completed.
Study NCT00004478   Information provided by Office of Rare Diseases (ORD)
First Received: October 18, 1999   Last Updated: September 17, 2008   History of Changes

October 18, 1999
September 17, 2008
March 1999
March 2006   (final data collection date for primary outcome measure)
 
 
Complete list of historical versions of study NCT00004478 on ClinicalTrials.gov Archive Site
 
 
 
Droxidopa in Treating Patients With Neurogenic Hypotension
Study of Droxidopa in Patients With Neurologic Hypotension

Please note that the continuation study can be found at http://clinicaltrials.gov/show/NCT00633880.

RATIONALE: Neurogenic hypotension is a fall in blood pressure that occurs when one moves from a lying down to a standing position or after eating a meal. It causes one to feel dizzy, light headed, and weak. Neurogenic hypotension is caused by a problem in the part of the nervous system that controls such functions as heart rate and blood pressure. Droxidopa, a drug that may increase blood pressure, may be an effective treatment for neurogenic hypotension.

PURPOSE: Clinical trial to study the effectiveness of droxidopa in treating patients who have neurogenic hypotension.

PROTOCOL OUTLINE:

Patients receive escalating doses of droxidopa or placebo for 7-14 days. Patients undergo blood pressure measurements hourly in both supine and standing positions.

 
Interventional
Treatment
  • Shy-Drager Syndrome
  • Orthostatic Hypotension
Drug: droxidopa
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
March 2006
March 2006   (final data collection date for primary outcome measure)

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Orthostatic hypotension due to autonomic nervous system failure Fall in systolic blood pressure (supine to standing) of at least 20 mm Hg and diastolic blood pressure of at least 15 mm Hg AND Symptoms of hypotension such as dizziness, light-headedness, unsteadiness, dimming or blurred vision
  • History of syncope or near-syncope

--Prior/Concurrent Therapy--

  • Endocrine therapy: No concurrent adrenergics Concurrent fludrocortisone allowed
  • Other: Concurrent indomethacin, support garments, and high salt diets allowed
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00004478
 
199/14180, MTS-GCO-98-243-3-NE
Mount Sinai School of Medicine
 
Study Chair: Horacio Kaufmann, MD New York University School of Medicine
Office of Rare Diseases (ORD)
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP